80mg/m2 administration for 14 days, followed by a resting period for 7 days.
Sponsors
PerSeUS-GP, PerSeUS: Perpetual Study estimated-by United Sections in gifu
Conditions
Locally advanced pancreatic cancer
Phase 2
A clinical phase-II trial of neoadjuvant chemoradiation therapy using S-1 for locally advanced pancreatic cancer (PerSeUS-GP-01)
Active, not recruitingJPRN-UMIN000002176
Start: 2009-08-01Target: 40Updated: 2026-06-29
A clinical phase-II trial of neoadjuvant chemoradiotherapy with S-1 and Gemcitabine for locally advanced pancreatic cancer (PerSeUS-GP02)
RecruitingJPRN-UMIN000010435
Start: 2013-04-12Target: 40Updated: 2026-06-29